ArticleClinical pharmacology in drug development2023

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose).

Deven V Parmar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.